Regeneron Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REGN research report →
Range $756 – $1100
Price Chart
About the company
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch).
- CEO
- Leonard S. Schleifer
- IPO
- 1991
- Employees
- 15,410
- HQ
- Tarrytown, NY, US
AI snapshot
Six angles, distilled from the data.
REGN remains in a powerful multi-month uptrend and is still trading well above its 200-day average of 746.9. The stock sits near its 52-week high of 991.73, which keeps the regime constructive, though it is extended after a large run rather than early in a base.
Street sentiment is firmly positive, with a Buy consensus and an average target of 977.9, modestly above the last close. Recent action has been mostly target raises and reiterated bullish calls, including 1,100 from Guggenheim and 1,065 from Jefferies, which reinforces the constructive setup.
The earnings profile is strong: REGN has beaten EPS in 7 of the last 8 quarters, including a 33.9% beat in the latest report. Next-year EPS estimates point higher to 62.12 from 45.24 TTM, so shareholders should watch whether growth and margin discipline keep supporting that trajectory.
The pattern is mixed but leans to net selling. Jason Pitofsky, an SVP Controller, had multiple sale transactions alongside offsetting exempt award-related entries, while Andrew Murphy reported a gift; the discretionary sell activity is the cleaner signal and suggests caution rather than accumulation.
Profitability is solid, with a 46.7% gross margin, 30.4% operating margin, and 28.5% net margin. Growth remains strong too, with revenue up 36.3% year over year and earnings up 35.5%, backed by $5.88 billion in free cash flow and $5.90 billion in net cash.
REGN screens as a premium large-cap biotech with stronger profitability than many peers, supported by high margins and net cash. The valuation is not cheap, but the setup is backed by durable cash generation and a consensus target that still leaves some upside from current levels.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.23B
- P/E
- 20.13
- Fwd P/E
- 13.49
- PEG
- 2.47
- P/S
- 5.79
- P/B
- 2.87
- EV/EBITDA
- 15.97
- Div Yield
- 0.39%
- Gross Margin
- 85.77%
- Op Margin
- 28.79%
- Net Margin
- 28.51%
- ROE
- 15.07%
- ROIC
- 10.59%
Latest fiscal year · YoY change
- Revenue
- $14.34B+1.0%
- Gross Profit
- $12.24B+0.1%
- Op Income
- $3.58B
- Net Income
- $4.50B+2.1%
- EPS
- $43.07+5.3%
- OCF Growth
- +12.6%
- FCF Growth
- +11.3%
- 52W High
- $991.73
- 52W Low
- $591.52
- 50D MA
- $826.97
- 200D MA
- $750.64
- Beta
- 0.24
- RSI (14)
- 58
- Avg Volume
- 804.03K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Regeneron delivered a strong quarter with 36% revenue growth and 70% EPS growth, while its core brands hit record sales and the pipeline advanced across neurology, NASH, oncology, obesity, and type 2 inflammation.· October 30, 2026
- Total revenue rose 36% year over year to $5.1 billion and non-GAAP diluted EPS increased 70% to $20.07.
- Dupixent, EYLEA HD, and Libtayo each posted all-time-high quarterly net sales again, with Dupixent global sales of $6.5 billion and U.S. sales of $5.1 billion.
- EYLEA HD U.S. sales reached about $700 million, up 62% year over year, and now represent nearly two-thirds of the U.S. retinal franchise.
- Libtayo global sales were $550 million, up 51% in constant currency, and management said it is now on an annual run rate of about $2.2 billion.
- Pipeline momentum was highlighted by cemdisiran, CIDEB in NASH, ubamatamab in ovarian cancer, and multiple next-gen Sanofi inflammation assets.
Third quarter total revenue increased 36% year over year to $5.1 billion. Non-GAAP diluted net income per share grew 70% to $20.07, on net income of $2.2 billion. Sanofi collaboration revenue reached a record $2.7 billion, including $2.6 billion from Regeneron’s share of collaboration profits, and the company said the full $1 billion upfront payment from the amended Sanofi antibody collaboration will be recorded in the fourth quarter. EYLEA HD U.S. sales were approximately $700 million, up 62% year over year, while combined EYLEA HD and EYLEA U.S. sales were $1.1 billion, down 1%. Libtayo worldwide sales were $550 million, up 51% in constant currency, and U.S. sales were nearly $400 million, up 81%. Management made modest refinements to 2026 guidance, said EYLEA HD should see about 10% sequential growth in the fourth quarter, and guided to full-year EYLEA HD net sales growth of over 50% versus 2025. Christopher Fenimore also said 2027 R&D expense is expected to rise by a mid-teens percentage versus 2026, and the 2027 effective tax rate should face about 100 to 200 basis points of upward pressure versus 2026.
Leonard Schleifer framed the quarter as exceptional, pointing to strong commercial execution and a pipeline that is “continuing to deliver on its promise.” He emphasized that the company’s science-led, disease-agnostic R&D model is producing multiple programs with first- or best-in-disease potential, and he highlighted the expanded Sanofi alliance as a way to extend Regeneron’s leadership in type 2 inflammation. His tone was confident and expansive, with repeated emphasis on long-term value creation and the breadth of the company’s platform.
Christopher Fenimore said the quarter was driven by higher Sanofi collaboration revenue plus strong growth from Libtayo and EYLEA HD. He cited third-quarter free cash flow of $2.9 billion through the first nine months of 2026, cash and marketable securities net of debt of $16.2 billion, and nearly $3 billion deployed year to date across buybacks, business development, and dividends; $2.3 billion of that went to repurchasing 3.2 million shares. He also said full-year share repurchases are expected to total about $3 billion, with $2.2 billion remaining under the authorization as of September 30, and noted that the third-quarter Ilaris royalty revenue included an approximately $60 million cumulative catch-up that will not recur in Q4.
Analysts focused on CIDEB’s differentiation versus other NASH approaches, and George Yancopoulos said the asset is unique because it directly targets a genetically validated pathway rather than acting indirectly through weight loss or other mechanisms; he described the early liver fat reductions as unprecedented. Questions also centered on cemdisiran launch readiness, where Marion McCourt said prelaunch activities are well underway and the team is “launch ready,” though she did not give launch strategy details. Other notable questions addressed the expanded Sanofi alliance, the next-gen type 2 inflammation antibodies, obesity competition, and PNH switching potential; management repeatedly stressed that they are open to multiple opportunities but want highly differentiated assets, and for PNH they said additional data are still needed before drawing firm conclusions.
The call reinforced that Regeneron’s three core growth brands are scaling at the same time, with Dupixent, EYLEA HD, and Libtayo all setting new quarterly highs. Management also described a deep and unusually broad pipeline, with several near-term catalysts and multiple programs that they believe could be first in class or best in disease, plus a strong balance sheet to support investment and buybacks.
Several programs are still dependent on upcoming regulatory decisions and data readouts, including cemdisiran, PNH, GA, and multiple mid- and late-stage assets. Management also acknowledged competitive pressure in retinal disease from biosimilars, ongoing pricing pressure on EYLEA, and said lynozyfic growth should remain modest for now as it moves earlier in therapy. In type 2 inflammation and obesity, management emphasized differentiation will matter, suggesting not every pipeline asset will be a clear winner.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.2%
- Shares Outstanding
- 103.43M
- Float Shares
- 99.55M
of shares held by institutions
1,402 13F filers
Buy/sell ratio 0.12. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for REGN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 4, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 7, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | May 15, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Feb 12, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 18, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 29, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Aug 26, 25 | Filing → |
| Robert P. BresnahanHouse · PA08 | Buy | May 15, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Sell | Apr 10, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Sell | Apr 10, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 9.08M | ▲ 26.88K |
| Blackrock, Inc. | 8.85M | ▼ 263.92K |
| Vanguard Capital Management LLC | 6.52M | ▼ 107.41K |
| State Street Corp | 4.88M | ▲ 46.67K |
| Dodge & Cox | 4.77M | ▼ 96.65K |
| Invesco Ltd. | 3.72M | ▼ 219.40K |
| Jpmorgan Chase & Co | 3.31M | ▼ 466.81K |
| Vanguard Portfolio Management LLC | 3.11M | ▼ 63.64K |
| Franklin Templeton Inc | 2.95M | ▲ 178.97K |
| Geode Capital Management, LLC | 2.63M | ▲ 7.02K |
| Nuveen, LLC | 1.96M | ▼ 64.03K |
| Loomis Sayles & Co L P | 1.72M | ▼ 142.53K |
Held by 2,280 ETFs
Biggest fund positions in REGN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | SING GEORGE L | sell | 1,000 |
| Nov 17, 26 | SING GEORGE L | sell | 176 |
| Nov 17, 26 | SING GEORGE L | sell | 359 |
| Nov 17, 26 | SING GEORGE L | sell | 465 |
| Nov 16, 26 | McCourt Marion | sell | 44 |
| Nov 16, 26 | McCourt Marion | sell | 59 |
| Nov 16, 26 | McCourt Marion | sell | 30 |
| Nov 16, 26 | McCourt Marion | sell | 22 |
| Nov 16, 26 | McCourt Marion | sell | 44 |
| Nov 16, 26 | McCourt Marion | sell | 66 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our REGN coverage
Recent articles, reports, and earnings notes.

Regeneron Pharmaceuticals (REGN): Growth Power, But Valuation Caps Upside
Regeneron posted 36% revenue growth and 70% EPS growth in Q3 2026, driven by record sales from Dupixent, EYLEA HD, and Libtayo. The stock still earns a Hold as valuation and franchise concentration temper the long-term story.

Biotech’s breakout is a catalyst trade, not a new market leader
Biotech’s sharp outperformance is real, but the rally is rewarding profitable franchises and identifiable catalysts rather than lifting the entire sector. The better opportunity is selective exposure to de-risked pipelines, not indiscriminate bets on biotech as technology’s replacement.

The rate-cut trade is splitting in two: buy biotech, not every growth stock
A softer July PCE report could revive duration, but the best rebound candidates are profitable, catalyst-backed biotechs rather than every cash-burning growth stock. If inflation keeps yields high, JPM and Goldman offer the more defensible earnings-supported trade.
Want a deeper read on REGN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Here's Why Regeneron (REGN) is a Strong Momentum Stock
zacks.com · Nov 20
2 Growth Stocks to Buy in November Without Any Hesitation
fool.com · Nov 19
REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
zacks.com · Nov 19
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
globenewswire.com · Nov 19
US FDA approves Regeneron's drug for generalized myasthenia gravis
reuters.com · Nov 18
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
globenewswire.com · Nov 18
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility
zacks.com · Nov 18
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval
marketbeat.com · Nov 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 15, 2026 · Live quote · Not investment advice